Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

Health, Absence, Disability, and Presenteeism: Cost Estimates of Certain Physical and Mental Health Conditions Affecting U.S. Employers

In this study, evidence about the total cost of health, absence, short-term disability, and productivity losses was synthesized for 10 health conditions. Cost estimates from a large medical/absence database were combined with findings from several published productivity surveys. Ranges of condition prevalence and associated absenteeism and presenteeism (on-the-job-productivity) losses were used to estimate condition-related costs. Based on average impairment and prevalence estimates, the overall economic burden of illness was highest for hypertension ($392 per eligible employee per year), heart disease ($368), depression and other mental illnesses ($348), and arthritis ($327). Presenteeism costs were higher than medical costs in most cases, and represented 18% to 60% of all costs for the 10 conditions. Caution is advised when interpreting any particular source of data, and the need for standardization in future research is noted.

Due to copyright issues, this study is only available through the JOEM website.

Newsletter Volume

E.V.I.dently June 2015

NPC MessageDriving Health System Value Through Broader Access to DataFrom Fitbits to insurance claims databases, we capture an enormous amount of...
Newsletter Volume

E.V.I.dently May 2015

MessageStepping Back to Look at ValueNPC President Dan Leonard explains that, like beauty, the value of health care is in the eye of the beholder....
Newsletter Volume

E.V.I.dently April 2015

MessageThe Health Care Paradigm Shift: Moving From Volume to ValueAs our health care payment and delivery systems shift from volume-based to...
Newsletter Volume

E.V.I.dently March 2015

NPC MessageCER and the Environment for Health Care Decision-MakingIs comparative effectiveness research (CER) having an impact on health care...
Press Release

NPC Welcomes Dr. Bryan Luce as PCORI Chief Science Officer

WASHINGTON, DC (April 24, 2013) The National Pharmaceutical Council today welcomed the news that the Patient-Centered Outcomes Research Institute (...
Press Release

Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Council’s Chairman of the Board

WASHINGTON, DC (November 2, 2012)–The National Pharmaceutical Council (NPC) today announced that John Gargiulo, President & CEO, Daiichi Sankyo,...
Press Release

Study Quantifies Impact of Pharmaceuticals on Enhanced Productivity

(WASHINGTON, DC, August 1, 2012)–The costs to employers of chronic health conditions on employee productivity are well documented, but few studies...
Press Release

Pharmaceuticals Play Key Role in Achieving ACO Quality, Cost Goals

WASHINGTON, DC, July 18, 2012–As health care providers set up accountable care organizations (ACOs) and other value-based care programs,...
Commentary and Testimony Page

Living Up to Its Name? The Role of Patient-Centered Research

Anyone who has ever received bad news from his or her health care provider or held a loved one’s hand when a diagnosis was delivered can understand...
Commentary and Testimony Page

High Stakes for Setting Research Standards

What is the cost of poorly designed research? In the comparative effectiveness arena, faulty studies could mean that consumers may make important...
Commentary and Testimony Page

Asymmetry in the Ability to Communicate CER Findings: Ethics and Issues for Informed Decision Making

The number of voices in the comparative effectiveness research (CER) conversation is continuing to grow, but not all stakeholders have the same...
Commentary and Testimony Page

Comparative Effectiveness Research and the Changing Health Care Landscape

This content appeared in the January 2, 2012 print edition of Chain Drug Review. In the span of just one year, the health care landscape has...
YouTube Videos

Engaging Consumers in Today's Changing Health Care Payment and Delivery Environment

The current health care delivery system is evolving from a fee-for-service system to one that is performance-based. How does this shift impact...
YouTube Videos

Shifting the Focus From "How Much" to "How Well" We Spend Our Health Care Dollars

A. Mark Fendrick, MD, director of the Center for Value-Based Insurance design at the University of Michigan, highlights the key findings from a...
YouTube Videos

Rapid-Learning Health Care Systems, Explained

Dr. Lucy Savitz, director of research and education, Institute for Healthcare Delivery Research, Intermountain Healthcare, explains rapid learning...
YouTube Videos

Can We Bring Clarity, Consistency and Transparency to Payer Coverage Decisions?

There is a bit of a "black box" around the formulary decision-making process. As a result, decisions about treatment access are often unpredictable...
Blog Post

Specialty Pharmaceutical and Patient Care: Are We at a Tipping Point?

Last month, the Academy of Managed Care Pharmacy (AMCP) Foundation hosted a symposium, “Specialty Pharmaceutical and Patient Care: Are We at a...
Blog Post

Assessing the Value of Drugs for Formulary Decisions

Some of the National Pharmaceutical Council's (NPC) research partners participated today on a panel, "Best Practices for Assessing the Value of Drugs...
Blog Post

#TBT: Consumer-Directed Health Plans & Employers’ Decision-Making

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Blog Post

#TBT: Bob Costas, Presenteeism and Its Impact on Productivity

As part of our “Throwback Thursday” blog series, we’re taking a look at a research topic that’s currently in the news and tagging it with previous...

Consumer-Directed Health Plans: Pharmacy Benefits & "Better Practices"

On behalf of the National Pharmaceutical Council, Th

Transparency in Evidence Evaluation and Formulary Decision-Making

Although the type of evidence required to make healt

  • 1 of 40
  • >